Finch Therapeutics Group (NASDAQ:FNCH) and SQZ Biotechnologies (NYSE:SQZ) Critical Survey
by Amy Steele · The Cerbat GemInstitutional & Insider Ownership
38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
SQZ Biotechnologies has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
Earnings & Valuation
This table compares SQZ Biotechnologies and Finch Therapeutics Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SQZ Biotechnologies | $18.16 million | 0.04 | -$79.46 million | ($2.61) | -0.01 |
| Finch Therapeutics Group | N/A | N/A | -$74.75 million | ($8.82) | -0.83 |
Finch Therapeutics Group has lower revenue, but higher earnings than SQZ Biotechnologies. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares SQZ Biotechnologies and Finch Therapeutics Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SQZ Biotechnologies | -369.96% | -119.83% | -59.90% |
| Finch Therapeutics Group | N/A | -69.14% | -26.92% |
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.